Agilon Health (AGL) Stock May Be Undervalued Following ACO Expansion

agilon health stock has logged a very large year to date gain, yet the broader valuation checks still flag it as looking cheap on multiple fronts. For anyone tracking that kind of move, the puzzle is whether this run simply catches up with fundamentals or if the current pricing still leaves room for more optimism already baked in.

• Year to date, agilon health is up about 433%, which puts a spotlight on whether recent enthusiasm already reflects the underlying business quality.
• The expanded relationship with Family Practice Center through a Senior Health Connect ACO can support long term value based care economics, while execution risk around managing full risk Medicare models may weigh on how much investors are willing to pay.
• On Simply Wall St’s broader checks, agilon health earns a high value score of 5 out of 6, which leans toward the stock screening as undervalued rather than fully priced.

The issue now is whether agilon health’s sharp re rating this year leaves investors paying a fair price for its value based care model or still buying into a discount.

Spot under-the-radar value-based care opportunities by comparing agilon health’s surge with 31 high quality undervalued stocks in similar high-quality, cash-generative businesses.

Does agilon health Look Undervalued on Sales?

P/S tends to fit agilon health because the story today is more about scaling revenue than about near term profits. On this yardstick, the stock trades at about 0.3x sales, far below the broader healthcare industry average of roughly 1.4x and the peer group near 2.0x. That is a wide gap for a business tied to recurring healthcare spending rather than one off product cycles.

The model driven fair P/S ratio for agilon health sits closer to 0.4x, which still comes in well under typical sector levels. Despite the recent Senior Health Connect ACO expansion with Family Practice Center, which has lifted attention on the ticker, the current multiple remains below that tailored fair value mark. The signal is that the market is not paying for its revenue base in line with either peers or the modelled benchmark.

On the P/S multiple, agilon health currently screens as undervalued relative to both its industry and the fair ratio estimate.

See what the numbers say about this price — find out in our valuation breakdown.

The agilon health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for agilon health leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth meaningfully more or less than today’s level. Each scenario ties a fair value to a clear set of potential catalysts and pressure points, so you can track over time which version of agilon health's story is taking shape on the Community page.

Community views on agilon health could hardly be further apart, with one camp focused on margin recovery and another on contract and execution risk.

Bull case: 19% undervalued

"Expansion of clinical pathways, successful scaling of chronic disease management programs, and strong PCP and patient retention reinforce agilon health's operational leverage…"

Read the full Bull Case to see why agilon health could be undervalued

Bear case: 308% overvalued

"Market exits, cost pressures, and payer negotiation risks threaten to undermine recurring revenue streams and limit sustainable growth in the value-based care sector…"

Read the full Bear Case to see why agilon health could be overvalued

Do you think there's more to the story for agilon health? Head over to our Community to see what others are saying!

The Bottom Line

agilon health screens as undervalued on its P/S ratio even after a very large year to date move, which suggests the market is still pricing the group cautiously against peers. The strong broader valuation checks add weight to that signal, but they do not resolve the core question around execution in full risk Medicare arrangements. The crux for investors is whether agilon health can convert its value based care model into resilient margins without running into contract or cost setbacks. That will likely decide whether the current discount reflects lingering risk or a mispriced opportunity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com